Evidence-based Recommendations for Gastrointestinal Stromal Tumors
An Oncology Exchange Program
A series of Live Grand Rounds Programs
Welcome to "Oncology Exchange: Evidence-based Recommendations for Gastrointestinal Stromal Tumors." This CME-certified initiative is intended for community-based medical oncologists and other health care professionals involved in the care of patients with gastrointestinal stromal tumors (GIST).
A series of live CME-certified programs will be presented at selected hospitals throughout the US during 2013/2014.
There is an increasing awareness among oncologists of the complex pathogenesis of GIST and the need to personalize therapy for every patient. A better understanding of the molecular characteristics of GIST has led to the discovery of novel treatment strategies and a significant transformation in the overall management of GIST patients.
Evidence-based Recommendations for GIST is intended to educate community oncologists and the other members of the multidisciplinary GIST care team on advances in the management of GIST, while also guiding clinicians in the selection of optimal treatment regimens for their patients, ultimately leading to improved patient outcomes.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about the accreditation of this program, please email email@example.com.
A calendar of live events, as well as additional CME/CE-certified online activities, for this and other Oncology Exchange programming, can be found at: www.medscape.org/sites/advances/oncologyexchange.
Live Program Materials for Speakers and Administrators
Back to Top
I. Administrator Material
II. Speaker Material
Thank you for joining us as an expert speaker for the Visiting Professor Series, "Oncology Exchange: Evidence-based Recommendations for GIST."
This orientation will familiarize you with the complete slide set, provide insight from the program steering committee, and address potential questions. The following key topics will be discussed:
- Understand and implement updated clinical practice guidelines to improve patient outcomes
- Assess the optimal treatment strategy for patients with very early stage disease (micro-GIST), localized disease, and metastatic disease
- Incorporate monitoring and surveillance strategies into practice for patients with resected or metastatic GIST
- Develop a multidisciplinary treatment approach for the management of GIST
Transcript of Speaker Orientation Download (PDF) (Coming Soon)
Audio download of Speaker Orientation (Coming Soon)
CME-certified Program Slides
This version of the program slides has been CME-certified and these slides are to be used for this activity. Download (PowerPoint)
RAPHAEL E. POLLOCK, MD, PhD
Professor of Surgery
Director of Surgical Oncology
Chief of Surgical Services
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Ohio State University Comprehensive Cancer Center
Raphael E. Pollock, MD, PhD, FACS was born in Chicago, IL and graduated from Oberlin College in Ohio in 1972. This was followed by medical school at the St. Louis University School of Medicine in Chicago, IL; residencies in general surgery at the University of Chicago and Rush Medical College; a fellowship in surgical oncology at the University of Texas MD Anderson Cancer Center; and a PhD in tumor immunology from the Graduate School of the Biological Sciences at the University of Texas-Houston Health Sciences Center. Dr. Pollock joined the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center as a faculty member in 1984. Dr. Pollock was named Chairman of the Department of Surgical Oncology in 1993 and became Head of the Division of Surgery at the MD Anderson Cancer Center in 1997.
Dr. Pollock has a professional dedication to the care of solid tumor patients, as well as to laboratory research in this field. His clinical and research activities focus on a rare form of connective tissue cancer known as soft tissue sarcoma. Dr. Pollock is a Professor of Surgery, the Director of Surgical Oncology, and the Chief of Surgical Services for the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute atthe Ohio State University Comprehensive Cancer Center in Columbus, OH.
JONATHAN C. TRENT, MD, PhD
Professor of Medicine
Director, Bone and Soft-tissue Sarcoma Program
Sylvester Comprehensive Cancer Center
University of Miami
Jonathan C. Trent, MD, PhD has 12 years of experience focusing on patient care, research, and education related to gastrointestinal stromal tumors (GIST). Dr. Trent has published numerous abstracts and research articles in leading journals, as well as book chapters, and is a frequently requested lecturer. He is the Chief Editor of the sarcoma section of Current Opinions in Oncology and serves on the editorial boards of the Chinese Journal of Clinical Oncology, Rare Tumors, and Translational Medicine. He also is a journal reviewer on a number of journals, including Nature Medicine, Lancet, Cancer, Clinical Cancer Research, and Cancer Research.
Dr. Trent's clinical interests focus on GIST patient care, clinical trials, and translational research. The excellence of his GIST clinical team led to his recognition as the 2010 GIST Physician of the Year by the LifeRaft Group. He is the Principal Investigator, as well as a collaborator, on several ongoing clinical trials that are examining the use of kinase inhibitors alone and in combination with novel drugs in patients with primary and metastatic GIST. He is a Principal Investigator on the ongoing GIST registry and is credited with several breakthroughs in GIST that stemmed from his 5-year National Institutes of Health K-23 GIST research grant.
Dr. Trent earned his undergraduate degree in chemistry at Southeastern Oklahoma State University and his medical doctorate and PhD in cancer biology from the University of Texas Health Science Center. He completed an internship and residency in internal medicine at the University of Texas Health Science Center, and a fellowship in medical oncology at the University of Texas MD Anderson Cancer Center, while serving as Chief Fellow. Dr. Trent is board-certified in internal medicine and medical oncology.